Navigation Links
Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
Date:1/28/2008

TORONTO, Jan. 28 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced it has completed its Pre-IND (Investigational New Drug) meeting with the FDA to discuss the upcoming IND submission for ARH460-16-2, its lead CD44 Cancer Stem Cell Program. ARH460-16-2 is an anti-cancer antibody targeting a novel epitope of CD44 found in hematological and solid cancers, including breast, colon and prostate. The Pre-IND meeting focused on development plans for the drug, including manufacturing details, preclinical pharmacology and toxicology data, and the proposed plans for the Phase I clinical program.

"The completion of our pre-IND meeting with the FDA is an important milestone for the Company and demonstrates the significant progress we have made with our lead CD44 Cancer Stem Cell Program and our ability to advance drug candidates towards human clinical trials," said Dr. David Young, President and Chief Executive Officer. "We are pleased with the outcome of this meeting and will continue to prepare for our IND submission with the intention of initiating human clinical trials this year."

Concurrently, ARIUS announced the promotion of Susan Hahn, PhD, formerly Director of Development, to the position of Vice President of Development. "Dr. Hahn has been instrumental in leading the development of our antibody programs that we are taking to the clinic," said Dr. Young. "In her new role, Dr. Hahn will continue to focus on meeting ARIUS' development milestones as we move each of our lead drug candidates towards human clinical trials."

The CD44 Cancer Stem Cell program was generated using ARIUS' proprietary FunctionFIRST(TM) technology, which selects antibodies based on their ability to kill cancer cells. Pre-clinical data from a dose-ranging pilot toxicology study in non-human primate models demonstrated no dose-limiting toxic effects at doses up
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
2. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
3. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
4. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. ARIUS to present at Chinese Global Financial Forum
7. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
8. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
9. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
10. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
11. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... day, their baby stopped breathing, his collapsed bronchus blocking ... and Bryan Gionfriddo watched helplessly, just praying that somehow ... doctors said he had a good chance of not ... now 20-month-old son, Kaiba. "At that point, we were ... and run with it." , They found hope at ...
(Date:5/23/2013)... 23, 2013 Graphite Metallizing Corporation ... bushings mounted in stainless steel pillow blocks. This ... GRAPHALLOY with the application and installation versatility of ... Blocks work exceptionally well when submerged in ... liquids such as acids, alkalies, hydrocarbons, black liquor, ...
(Date:5/23/2013)... 23, 2013 The maker community is ... of inventions. They focus on learning practical skills while ... gravitate toward bringing their ideas to life via crowdfunding. ... works on making projects using biology. Glowing Plant has ... to make them glow with bioluminescence genes, and has ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
Breaking Biology Technology:Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... Calif., Aug. 30 Cepheid (Nasdaq:,CPHD) will present ... at the Four Seasons Hotel, Boston, September 5 ... and Senior Vice President, Finance and,Chief Financial Officer, ... ET on,September 7. The webcast, along with ...
... Aug. 30 Verenium,Corporation (Nasdaq: VRNM ), a ... the development of high-performance specialty,enzymes, announced today that Carlos ... be presenting at the Cowen and Company Clean,Energy Conference. ... ET,on Thursday, September 6, 2007 and will take place ...
... 30 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... and CEO will present at the 2007 UBS ... the Grand Hyatt New York on Wednesday,September 26 ... ) A live webcast of the presentation ...
Cached Biology Technology:Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 3Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... the implications for the overall health, development, and ... primary role in ensuring that all students have ... per day of vigorous or moderate-intensity physical activity, ... Medicine. Recent estimates suggest that only about ... for promoting better health and development. The ...
(Date:5/23/2013)... medics have succeeded in treating cerebral palsy with autologous ... damage, a 2.5 year old boy had been in ... survival. Just two months after treatment with the cord ... the following months, the child learned to speak simple ... from a Korean study, dispel the long-held doubts about ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... is most well-known both for his book "On the Origin of ... do not think anything in my scientific life has given me ... of these plants." What could be more satisfying than ... to his studies of different forms of hermaphroditic flowers that occur ...
... , an internationally recognized expert at the University of ... been chosen by the U.S. Department of State to ... Miller is one of only ten persons selected for ... rigorous selection process, are highly accomplished in fields of ...
... gowns and bed sheets to match a patient,s skin color ... other health-related skin color changes, according to a new study ... patient, and then sees the patient again later, the doctor ... has changed color," said neurobiologist and study leader Mark Changizi, ...
Cached Biology News:'Different forms of flowers' continues to fascinate 2US Department of State names UCR entomologist a Jefferson Science Fellow 2US Department of State names UCR entomologist a Jefferson Science Fellow 3Nude-colored hospital gowns could help doctors better detect hard-to-see symptoms 2
... ZMD.368. Immunogen: Synthetic peptide derived ... human WNT2B/WNT13 protein. Specificity: Specific ... and rat WNT2B/WNT13 proteins. Recognizes both ... Reactivity: Mouse Human Rat (positive controls: ...
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
... I-96 Plate can be used either in ... large-scale (i.e., 96-well) purification of DNA and/or ... unique silica-based matrix make it perfect for ... RNA in = 10 l eluate per ...
Biology Products: